Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis
暂无分享,去创建一个
Mario Fusaro | E. Hannan | D. Faxon | S. Bangalore | F. Feit | Edward L Hannan | David P Faxon | Sripal Bangalore | N. Amoroso | Frederick Feit | Sunil K. Kumar | Nicholas Amoroso | Bora Toklu | Sunil Kumar | B. Toklu | Mario V. Fusaro | Mario V Fusaro | Bora Toklu
[1] Armando Pérez de Prado,et al. Role of the Paclitaxel-Eluting Stent and Tirofiban in Patients With ST-Elevation Myocardial Infarction Undergoing Postfibrinolysis Angioplasty: The GRACIA-3 Randomized Clinical Trial , 2010, Circulation. Cardiovascular interventions.
[2] P. Serruys,et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.
[3] David S. Moore,et al. Statistics in Practice , 2014 .
[4] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[5] F. Eberli,et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.
[6] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[7] J. Ottervanger,et al. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. , 2009, The American journal of cardiology.
[8] F. Varbella,et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). , 2008, The American journal of cardiology.
[9] P. Fitzgerald,et al. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. , 2010, Journal of the American College of Cardiology.
[10] F. Eberli,et al. Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial , 2011, Circulation.
[11] J. Tijssen,et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. , 2012, JACC. Cardiovascular interventions.
[12] J. Tijssen,et al. Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[13] M. Buchbinder,et al. A randomized comparison of sirolimus‐eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: The DECODE study , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] D. Ardissino,et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. , 2009, European heart journal.
[15] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[16] Hiroshi Takahashi,et al. Sirolimus-eluting stent vs. everolimus-eluting stent for coronary intervention in patients on chronic hemodialysis. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[17] J. Marchesini,et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.
[18] J. M. de la Torre Hernández,et al. A real all-comers randomized trial comparing Xience Prime and Promus Element stents. , 2013, The Journal of invasive cardiology.
[19] E. Omerovic,et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). , 2012, European heart journal.
[20] A. Kastrati,et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.
[21] Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials , 2012, Circulation.
[22] G. De Luca,et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. , 2009, JACC. Cardiovascular interventions.
[23] B. Gersh,et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. , 2009, The New England journal of medicine.
[24] E. Ribeiro,et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[25] P. Serruys,et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.
[26] G. Stone,et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. , 2012, Archives of internal medicine.
[27] P. Serruys,et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial , 2012, The Lancet.
[28] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.
[29] Dick M. Goedhart,et al. Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[30] J. W. Louwerenburg,et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. , 2013, Journal of the American College of Cardiology.
[31] A. Colombo,et al. TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[32] A. Erglis,et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. , 2007, Journal of the American College of Cardiology.
[33] A. Kirtane,et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. , 2009, Journal of the American College of Cardiology.
[34] Y. Hayashi,et al. TCT-625 Three Year Follow up of a Randomized Comparison of Nobori, Biolimus A9 Eluting Stent(BES) with Cypher, Sirolimus Eluting Stent(SES) for Coronary Revascularization in Japanese Population , 2012 .
[35] J. Tijssen,et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Ele , 2011, JACC. Cardiovascular interventions.
[36] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[37] M. Jeong,et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. , 2009, The American journal of cardiology.
[38] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[39] P. Serruys,et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. , 2006, JAMA.
[40] M. Jeong,et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. , 2010, Journal of the American College of Cardiology.
[41] F. Chirillo,et al. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. , 2010, European heart journal.
[42] Volker Klauss,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.
[43] H. Bøtker,et al. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. , 2012, JACC. Cardiovascular interventions.
[44] I. Seong,et al. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. , 2011, JACC. Cardiovascular interventions.
[45] J. Popma,et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.
[46] P. Serruys,et al. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[47] A. Kastrati,et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. , 2008, European heart journal.
[48] G. Biondi Zoccai,et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). , 2007, Journal of interventional cardiology.
[49] R. Ferrari,et al. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. , 2009, Journal of the American College of Cardiology.
[50] S. Silber,et al. Final 5-Year Results of the TAXUS II Trial: A Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for De Novo Coronary Artery Lesions , 2009, Circulation.
[51] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[52] J. Stauffer,et al. Three‐year follow‐up of the first prospective randomized comparison between paclitaxel and sirolimus stents: The TAXi‐LATE trial , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[53] J. Suárez de Lezo,et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. , 2007, American heart journal.
[54] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[55] P. Fitzgerald,et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.
[56] I. Seong,et al. Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial , 2011, Circulation.
[57] A. Kirtane,et al. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. , 2013, JACC. Cardiovascular interventions.
[58] S. Takiuchi,et al. Comparison of real-world clinical outcomes between Cypher- and Taxus-eluting stents: the GARA–GARA study , 2011, Cardiovascular intervention and therapeutics.
[59] Y. Hayashi,et al. Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.
[60] Jonathan J Deeks,et al. metan-an alternative meta-analysis command , 1999 .
[61] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[62] I. Seong,et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. , 2011, JACC. Cardiovascular interventions.
[63] P. Serruys,et al. Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.
[64] B. Gersh,et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial , 2011, The Lancet.
[65] P. Teirstein,et al. Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[66] F. Prati,et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. , 2008, JAMA.
[67] H. Putter,et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. , 2008, Journal of the American College of Cardiology.
[68] I. Seong,et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. , 2008, Journal of the American College of Cardiology.
[69] J. Stauffer,et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. , 2005, Journal of the American College of Cardiology.
[70] C. Terkelsen,et al. Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.
[71] H. Bøtker,et al. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. , 2012, Journal of the American College of Cardiology.
[72] J. Suárez de Lezo,et al. Randomized study comparing everolimus‐ and sirolimus‐eluting stents in patients with bifurcation lesions treated by provisional side‐branch stenting , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[73] M. Pfisterer,et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis , 2008, BMJ : British Medical Journal.
[74] A. Wieczorek,et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. , 2008, European heart journal.
[75] Lefeng Wang,et al. [Efficacy comparison of primary percutaneous coronary intervention with biodegradable polymer- and durable polymer-based sirolimus-eluting stents for patients with acute myocardial infarction]. , 2010, Zhonghua xin xue guan bing za zhi.
[76] G. Stone,et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). , 2009, JACC. Cardiovascular interventions.
[77] J. Tijssen,et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. , 2006, The New England journal of medicine.
[78] A. Kribben,et al. Prolonged cold storage using a new histidine-tryptophan-ketoglutarate-based preservation solution in isogeneic cardiac mouse grafts. , 2011, European heart journal.
[79] G. De Luca,et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. , 2009, American heart journal.
[80] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[81] C. Terkelsen,et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial , 2013, The Lancet.
[82] P. Serruys,et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[83] F. Prati,et al. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). , 2013, International journal of cardiology.
[84] A. Kirtane,et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials , 2012, BMJ : British Medical Journal.
[85] Gregg W Stone,et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.
[86] Simon Wandel,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.
[87] J. Popma,et al. Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice , 2005, Circulation.
[88] F. Eberli,et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[89] Hiram G Bezerra,et al. Strut Coverage and Vessel Wall Response to a New-Generation Paclitaxel-Eluting Stent With an Ultrathin Biodegradable Abluminal Polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI) , 2010, Circulation. Cardiovascular interventions.
[90] F. Eberli,et al. TCT-44 LEADERS: 5-Year Follow-Up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Biodegradable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer- Final report of the LEADERS study , 2012 .
[91] A. Kastrati,et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. , 2009, European heart journal.
[92] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[93] Byung Ok Kim,et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[94] I. Olkin,et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.
[95] R. Ferrari,et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). , 2013, European heart journal.
[96] A. Erglis,et al. Are paclitaxel-eluting stents better in unprotected left main coronary artery disease? Three-year clinical and intravascular imaging results from a randomized study. , 2011, Medicina.
[97] J. Tijssen,et al. TCT-440 Two-year Clinical Outcomes Of Primary Stenting Of Totally Occluded Native Coronary Arteries III (PRISON III): A Randomized Comparison Of Sirolimus-Eluting Stent Implantation With Zotarolimus-Eluting Stent Implantation For The Treatment Of Total Coronary Occlusions , 2012 .
[98] H. Bøtker,et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. , 2008, JAMA.
[99] P. Fitzgerald,et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. , 2006, Journal of the American College of Cardiology.
[100] E. Bramucci,et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.
[101] I. Seong,et al. Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. , 2011, International journal of cardiology.
[102] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[103] D. Atsma,et al. Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[104] H. Bøtker,et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. , 2008, Journal of the American College of Cardiology.
[105] P. Fitzgerald,et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary , 2011, JACC. Cardiovascular interventions.
[106] A. Kastrati,et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. , 2009, Journal of the American College of Cardiology.
[107] Hong-Bing Yan,et al. Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. , 2007, Chinese medical journal.
[108] P. Serruys,et al. Four‐year clinical follow‐up of the XIENCE V everolimus‐eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[109] Giuseppe Musumeci,et al. Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.
[110] J. Suh,et al. A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial. , 2012, Chinese medical journal.
[111] Yuji Ikari,et al. Randomized comparison of the nobori biolimus A9‐eluting stent with the sirolimus‐eluting stent in patients with stenosis in native coronary arteries , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[112] M. De Carlo,et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. , 2007, Journal of the American College of Cardiology.
[113] I. Seong,et al. Prospective randomized comparison of sirolimus‐ versus paclitaxel‐eluting stents for the treatment of acute ST‐elevation myocardial infarction , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[114] G. Patti,et al. Long-term outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial. , 2013, International journal of cardiology.
[115] William Wijns,et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.
[116] F. Eberli,et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.
[117] P. Smits,et al. Objectives Background Methods Results Conclusions , 2022 .
[118] M. Jeong,et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. , 2011, Journal of the American College of Cardiology.
[119] R. Ferrari,et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. , 2005, JAMA.
[120] P. Smits,et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. , 2012, American heart journal.
[121] I. Seong,et al. Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease , 2006, Circulation.
[122] E. Bramucci,et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. , 2004, JAMA.
[123] H. Bøtker,et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. , 2009, The American journal of cardiology.
[124] A. Branzi,et al. Randomized comparative trial of a thin‐strut bare metal cobalt‐chromium stent versus a sirolimus‐eluting stent for coronary revascularization , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[125] Ya‐Ling Han,et al. [Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease]. , 2006, Zhonghua xin xue guan bing za zhi.
[126] Gregg W Stone,et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.
[127] W. Voelker,et al. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in , 2012, American heart journal.
[128] A. M. Leone,et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. , 2011, JACC. Cardiovascular interventions.
[129] P. Serruys,et al. Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2 , 2009, Circulation. Cardiovascular interventions.
[130] David Antoniucci,et al. Efficacy and safety of a double‐coated paclitaxel‐eluting coronary stent: The EUCATAX trial , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[131] B. Rensing,et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions , 2006, Circulation.
[132] H. Bøtker,et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. , 2006, Journal of the American College of Cardiology.
[133] J. Fajadet,et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. , 2012, Journal of the American College of Cardiology.
[134] D. Spiegelhalter,et al. Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .
[135] S. Chae,et al. Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. , 2008, Journal of interventional cardiology.
[136] M. Law. Outcome Measurement in Pediatric Rehabilitation , 2003, Physical & occupational therapy in pediatrics.
[137] L. Räber,et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. , 2012, JAMA.
[138] P. Serruys,et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial , 2011, The Lancet.
[139] P. Teirstein,et al. THREE–YEAR RESULTS OF THE PLATINUM RANDOMIZED TRIAL COMPARING PLATINUM CHROMIUM PROMUS ELEMENT AND COBALT CHROMIUM PROMUS/XIENCE v EVEROLIMUS–ELUTING STENTS , 2013 .
[140] M. Hadamitzky,et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. , 2011, Journal of the American College of Cardiology.
[141] M. Gawaz,et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. , 2009, Circulation. Cardiovascular interventions.
[142] M. Togni,et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial , 2013, The Lancet.
[143] Gregg W. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .
[144] Seung‐Jung Park,et al. Comparison of Resolute Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With De Novo Long Coronary Artery Lesions: A Randomized LONG-DES IV Trial , 2012, Circulation. Cardiovascular interventions.
[145] Ángel Martínez,et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. , 2007, American heart journal.
[146] S. Chae,et al. Comparison of three‐year clinical outcomes between sirolimus‐versus paclitaxel‐eluting stents in diabetic patients: Prospective randomized multicenter trial , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[147] Hiroshi Takahashi,et al. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients. , 2013, International journal of cardiology.
[148] H. Bøtker,et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial , 2010, The Lancet.
[149] P. Serruys,et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[150] P. Buser,et al. Incremental Cost-Effectiveness of Drug-Eluting Stents Compared With a Third-Generation Bare-Metal Stent in a Real-World Setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) , 2005 .
[151] Seung‐Jung Park,et al. Differential long‐term outcomes of zotarolimus‐eluting stents compared with sirolimus‐eluting and paclitaxel‐eluting stents in diabetic and nondiabetic patients: Two‐year subgroup analysis of the ZEST randomized trial , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[152] Gregg W Stone,et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.
[153] E. Bramucci,et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). , 2011, JACC. Cardiovascular interventions.
[154] H. Drexler,et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. , 2007, Journal of the American College of Cardiology.
[155] N. Aslanabadi,et al. The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer. , 2011, Journal of cardiovascular and thoracic research.
[156] I. McEwen. A Long and Valuable Partnership , 2003, Physical & Occupational Therapy in Pediatrics.
[157] G. Condorelli,et al. Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial: A Randomized Comparison of 3 Drug-Eluting Stents in Diabetic Patients , 2011, Circulation. Cardiovascular interventions.
[158] K. Hauptmann,et al. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[159] A. Kastrati,et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. , 2006, European heart journal.
[160] K. Seung,et al. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CAtholic Total Occlusion Study (CATOS) trial. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[161] Arianna Azzellino,et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). , 2007, Journal of the American College of Cardiology.
[162] A. Kastrati,et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. , 2010, Journal of the American College of Cardiology.
[163] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[164] A. Kirtane,et al. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[165] J. W. Louwerenburg,et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. , 2012, Journal of the American College of Cardiology.